Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Neuropsychiatric Therapies in Alzheimer’s Disease (US)
In 2023, Lundbeck / Otsuka’s Rexulti became the first FDA-approved drug to treat agitation associated with Alzheimer’s disease (AD). Other novel agents are now emerging as potential treatments…
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
Myasthenia Gravis – Current Treatment – Current Treatment: Physician Insights – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder primarily caused by autoantibodies targeting acetylcholine (ACh) receptors and therefore affecting neuromuscular synaptic transmission at the…
Alzheimer’s Disease – Current Treatment – Current Treatment: Physician Insights – Alzheimer’s Disease (US)
Alzheimer’s disease (AD) affects cognition and may bring a spectrum of neuropsychiatric symptoms (e.g., agitation, aggression, psychosis) that intensify as the disease advances. Important new…
